Electrocardiographic signs of acute right ventricular hypertrophy in patients with COVID-19 pneumonia: A clinical case series.

Martínez-Mateo, Virgilio; Fernández-Anguita, Manuel; Paule, Antonio

doi:10.1016/j.jelectrocard.2020.07.007

Cited by 6 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the time it was introduced, SI has been used as a more significant parameter in cases of hemorrhagic shock; i.e., presence of a rapid volume change (3). Systemic infection and myocarditis due to COVID-19 more often cause right ventricular hypertrophy and acute insufficiency symptoms, which have higher adaptability to volume changes (23). In this regard, while the systolic pressure and pulse values of patients may be affected later, this pathophysiological point of view supports the results of our study.…”

Section: Discussionsupporting

confidence: 88%

Comparison of the ability of the shock index, modified shock index and age shock index to predict mortality in geriatric patients with COVID-19 pneumonia

Tekyol

Hökenek

2021

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Comparison of the ability of the shock index, modified shock index and age shock index to predict mortality in geriatric patients with COVID-19 pneumonia

Tekyol

Hökenek

2021

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

show abstract

“…The meta-analysis performed herein also found that chronic respiratory illness significantly increased the incidence of SARS-CoV-2 associated cardiac complications. It is possible that these data reflect the established indirect association between severe respiratory disease and subsequent acute cardiovascular event Indeed, COVID-19 patients with pneumonia and acute respiratory distress syndrome (ARDS) display acute right ventricular hypertrophy despite an absence of pulmonary embolism or severe pulmonary hypertension [87]. However, chronic lung disease has not been consistently associated with SARS-CoV-2 ARDS and hypoxemia [88], and thus this is unlikely to be the sole explanation for the increased risk of cardiac complications in patients with chronic respiratory illness in the present analysis.…”

Section: Discussionmentioning

confidence: 99%

The role of pre-existing chronic disease in cardiac complications from SARS-CoV-2 infection: A systematic review and meta-analysis

Sinclair

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

Importance: SARS-CoV-2 is associated with multiple direct and indirect effects to the heart. It is not yet well defined whether patient groups at increased risk of severe respiratory disease due to SARS-CoV-2 infection also experience a heightened incidence of cardiac complications. Objective: We sought to analyse the role of pre-existing chronic disease (chronic respiratory illness, cardiovascular disease (CVD), hypertension and diabetes mellitus) in the development of cardiac complications from SARS-CoV-2. Data Sources: We retrospectively investigated published (including pre-prints), publicly released, de-identified, data made available between Dec 1, 2019, and May 11, 2020. Information was accessed from PubMed, Embase, medRxiv and SSRN. Study Selection: 379 full-text articles were reviewed and 321 excluded for lack of original research, irrelevance to outcome, inappropriate cohort, or small patient numbers (case reports of <10 patients). Data were extracted from two studies and the remaining 56 contacted to request appropriate data, to which three responded with data contributions. A final of five studies were included. Data Extraction and Synthesis: This systematic review was conducted based on PRISMA and MOOSE statements. Included studies were critically appraised using Newcastle Ottawa Quality Assessment Scale (NOS). Data were extracted independently by multiple observers. A fixed-effects model was selected for the meta-analysis based on relatively low heterogeneity between the studies (I2<50%). Main Outcome and Measures: Cardiac complications were determined via blood levels of cardiac biomarkers above the 99th percentile of the upper reference limit, abnormalities in electrocardiography, and/or abnormalities in echocardiography. Results: SARS-CoV-2-infected patients who developed cardiac complications were, on average, 10 years older than those that did not. Pooled analyses showed the development of cardiac complications from SARS-CoV-2 was significantly increased in patients with underlying chronic respiratory illness (OR 2.88[1.45,5.71]), CVD (OR 5.12[3.09,8.48]), hypertension (OR 4.37[2.99,6.39]) and diabetes mellitus (OR 2.61[1.67,4.09]). Conclusions and Relevance: Older age and pre-existing chronic respiratory illness, CVD, hypertension, and diabetes mellitus may represent prognostic factors for the development of additional cardiac complications in COVID-19, highlighting the need for a multidisciplinary approach to chronic disease patient management and providing justification for a larger scale observational study.

show abstract

“…The authors observed that patients with severe COVID-19 tend to develop "an atypical form of ARDS [acute respiratory stress syndrome] with significant dissociation between relatively well-preserved lung mechanics and severe hypoxemia." Similarly, Martínez-Mateo et al [17] state that "right ventricular (RV) overload and RV failure are common" in patients who had COVID-19 and related pneumonia and developed ARDS; they also noted that four of their patients developed dilatation in the right cavities of the heart and that PH was absent among all six of their case studies. On the other hand, another study found that among their participants that had COVID-19 pneumonia, 41% had RV dilatation and 27% developed RV dysfunction [18].…”

Section: Heart Structure Changes In Patients With Covid-19mentioning

confidence: 96%

Right Ventricular Hypertrophy among COVID-19 Patients

Yusuf¹,

Ram²

2022

Preprint

View full text Add to dashboard Cite

COVID-19 affects many organs in our body, including the heart and lungs. COVID-19 cases that require hospitalization often exhibit pulmonary hypertension (PH) due to changes in the lung microvasculature in which the blood vessels become stiff, damaged, or narrow, causing increased pulmonary arterial pressure. This review examines the hypothesis that PH can lead to right ventricular hypertrophy (RVH) as a long-lasting aftereffect of COVID-19. Recent studies have shown that significant percentages of hospitalized patients develop right ventricular hypertension and right ventricular dilatation (RVD), which may lead to right ventricular failure and death. Despite recommendations for echocardiogram reports to include right ventricular wall thickness to assess RVH, few published reports have reported this parameter. Relevant studies on animal models of PH in which the timing of PH can be precisely controlled suggest that one to three weeks of PH can cause RVH. Thus, according to the hypothesis proposed here COVID-19 patients who have long-lasting severe disease (e.g., needed to be on a ventilator for one or more weeks) accompanied by PH and RVD may develop RVH as a long-lasting sequela outlasting the infection itself. Echocardiogram studies of recovered COVID-19 patients may determine whether oft-reported cardiovascular sequelae include RVH.

show abstract

Electrocardiographic signs of acute right ventricular hypertrophy in patients with COVID-19 pneumonia: A clinical case series.

Cited by 6 publications

References 7 publications

Comparison of the ability of the shock index, modified shock index and age shock index to predict mortality in geriatric patients with COVID-19 pneumonia

Comparison of the ability of the shock index, modified shock index and age shock index to predict mortality in geriatric patients with COVID-19 pneumonia

The role of pre-existing chronic disease in cardiac complications from SARS-CoV-2 infection: A systematic review and meta-analysis

Right Ventricular Hypertrophy among COVID-19 Patients

Contact Info

Product

Resources

About